NR2F6 nuclear receptor inhibitor (Oncology Pharma)

N/A

Report date: 2025/03/20 09:57:04
NME

Base Information

Drug NameNR2F6 nuclear receptor inhibitor (Oncology Pharma)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNR2F6 protein inhibitors
TargetsNR2F6 protein
Therapy Area/IndicationsColonic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKcl Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOncology Pharma Inc
Inactive CompaniesN/A
Active IndicationsColonic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A